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Introduction 
 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to elicit 
those anti-cancer therapies which might be associated with either a considerable impact on financial 
resources or a substantial health benefit.  
For the 21st prioritisation (December 2014), 12 were filteredout of 169 identified drugs and were sent 
to prioritisation. Of these, 6 drugs were ranked as ‘highly relevant’ by the expert panel, 5 as ‘relevant’ 
and 1 as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, abstracts 
of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all drugs are provided in the following table. 
No Filtered Drugs - 20th prioritisation 3rd quarter 2014 Overall category 
1.  Vandetanib (Zactima®) for 2nd line therapy of advanced or metastatic 
NSCLC Relevant 
2.  Bevacizumab (Avastin®) plus chemotherapy  as 2nd line therapy for 
HER2 negative locally recurrent or metastatic breast cancer that has 
progressed after first-line treatment with bevacizumab plus chemotherapy 
Highly relevant 
3.  Bevacizumab (Avastin®) maintenance therapy in HER2-negative 
metastatic breast cancer that has not progressed during first-line 
docetaxel plus bevacizumab therapy 
Highly relevant 
4.  Adjuvant trastuzumab (Herceptin®) in node-positive, HER2 positive breast 
cancer patients Highly relevant 
5.  Olaparib (Lynparza®) for the maintenance treatment of platinum‑sensitive 
relapsed BRCA‑mutated high grade serous epithelial ovarian, fallopian 
tube, or primary peritoneal cancer 
Relevant 
6.  Gemcitabine (Gemzar®) prior to autologous stem cell transplant for 
relapsed or refractory aggressive histology non-hodgkin's lymphoma Relevant 
7.  Panobinostat (Faridak®) for relapsed multiple myeloma Relevant 
8.  Cobimetinib (GDC-0973, XL-518) for the first-line therapy of unresectable 
locally advanced or metastatic melanoma Highly relevant 
9.  Nivolumab (BMS-936558, MDX1106, ONO4538) as first line therapy for 
unresectable or metastatic melanoma Highly relevant 
10.  Irinotecan (Campto®) in advanced gastric adenocarcinoma Not relevant 
11.  Oxaliplatin (Eloxatin®) for the adjuvant therapy of stage II, IIIa and IIIb 
gastric adenocarcinoma Relevant 
12.  Bevacizumab (Avastin®) for stage IVB, recurrent or persistent carcinoma 
of the cervix Highly relevant 
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1 Breast Cancer 
1.1 Bevacizumab (Avastin®) plus chemotherapy  as 2nd line 
therapy for HER2 negative locally recurrent or metastatic breast 
cancer that has progressed after first-line treatment with 
bevacizumab plus chemotherapy 
Drug description: anti-VEGF antibody 
Incidence in Austria: 5,400 breast cancer patients 
EMA/FDA licensingfor this indication: -/- 
Phase III results: 
Minckwitz et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line 
treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after 
first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised 
phase 3 trial. The Lancet Oncology (2014) 15 (11) 1269 – 1278. 
 
Background 
Combining bevacizumab with first-line or second-line chemotherapy improves progression-free 
survival in HER2-negative locally recurrent or metastatic breast cancer. We assessed the efficacy and 
safety of further bevacizumab therapy in patients with locally recurrent or metastatic breast cancer 
whose disease had progressed after treatment with bevacizumab plus chemotherapy. 
 
Methods 
Using In this open-label, randomised, phase 3 trial, we recruited patients who had HER2-negative 
locally recurrent or metastatic breast cancer that had progressed after receiving 12 weeks or more of 
first-line bevacizumab plus chemotherapy from 118 centres in 12 countries. Patients were randomly 
assigned (1:1) by use of a central interactive voice response system using a block randomisation 
schedule (block size four) stratified by hormone receptor status, first-line progression-free survival, 
selected chemotherapy, and lactate dehydrogenase concentration, to receive second-line single-agent 
chemotherapy either alone or with bevacizumab (15 mg/kg every 3 weeks or 10 mg/kg every 2 
weeks). Second-line therapy was continued until disease progression, unacceptable toxicity, or 
consent withdrawal. At progression, patients randomly assigned to chemotherapy alone received third-
line chemotherapy without bevacizumab; those randomly assigned to bevacizumab continued 
bevacizumab with third-line chemotherapy. The primary endpoint was progression-free survival from 
randomisation to second-line progression or death in the intention-to-treat population. This trial is 
ongoing, and registered with ClinicalTrials.gov, number NCT01250379. 
 
Results 
Between Feb 17, 2011, and April 3, 2013, 494 patients were randomly assigned to treatment (247 in 
each group). The median duration of follow-up at the time of this prespecified primary progression-free 
survival analysis was 15·9 months (IQR 9·1–21·7) in the chemotherapy-alone group and 16·1 months 
(10·6–22·7) in the combination group. Progression-free survival was significantly longer for those 
patients treated with bevacizumab plus chemotherapy than for those with chemotherapy alone 
(median: 6·3 months [95% CI 5·4–7·2] vs 4·2 months [3·9–4·7], respectively, stratified hazard ratio 
[HR] 0·75 [95% CI 0·61–0·93], two-sided stratified log-rank p=0·0068). The most common grade 3 or 
more adverse events were hypertension (33 [13%] of 245 patients receiving bevacizumab plus 
chemotherapy vs 17 [7%] of 238 patients receiving chemotherapy alone), neutropenia (29 [12%] vs 20 
[8%]), and hand-foot syndrome (27 [11%] vs 25 [11%]). Grade 3 proteinuria occurred in 17 (7%) of 245 
patients receiving combination therapy and one (<1%) of 238 patients receiving chemotherapy alone. 
Serious adverse events were reported in 61 (25%) of 245 patients receiving bevacizumab plus 
chemotherapy versus 44 (18%) of 238 patients receiving chemotherapy alone. 
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Conclusion 
These results suggest that continued VEGF inhibition with further bevacizumab is a valid treatment 
option for patients with locally recurrent or metastatic HER2-negative breast cancer whose disease 
was stabilised or responded to fi rst-line bevacizumab with chemotherapy. 
1.2 Bevacizumab (Avastin®) maintenance therapy in HER2-
negative metastatic breast cancer that has not progressed 
during first-line docetaxel plus bevacizumab therapy 
Drug description: anti-VEGF antibody 
Incidence in Austria: 5,400 breast cancer patients 
EMA/FDA licensingfor this indication: -/- 
Phase III results: 
Gligorov et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after 
initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast 
cancer (IMELDA): a randomised, open-label, phase 3 trial The Lancet Oncology (2014) 15 (12) 
1351-1360.  
 
Background 
Longer duration of first-line chemotherapy for patients with metastatic breast cancer is associated with 
prolonged OS and improved progression-free survival. We investigated capecitabine added to 
maintenance bevacizumab after initial treatment with bevacizumab and docetaxel in this setting. 
 
Methods 
We did this open-label randomised phase 3 trial at 54 hospitals in Brazil, China, Egypt, France, Hong 
Kong, India, Italy, Poland, Spain, and Turkey. We enrolled patients with HER2-negative measurable 
metastatic breast cancer; each received three to six cycles of first-line bevacizumab (15 mg/kg) and 
docetaxel (75–100 mg/m²) every 3 weeks. Progression-free patients were randomly assigned with an 
interactive voice-response system by block (size four) randomisation (1:1) to receive either 
bevacizumab and capecitabine or bevacizumab only (bevacizumab 15 mg/kg on day 1; capecitabine 
1000 mg/m² twice per day on days 1–14, every 3 weeks) until progression, stratified by oestrogen 
receptor status (positive vs negative), visceral metastases (present vs absent), response status (stable 
disease vs response vs non-measurable), and lactate dehydrogenase concentration (≤1·5 vs >1·5 × 
upper limit of normal). Neither patients nor investigators were masked to allocation. The primary 
endpoint was progression-free survival (from randomisation) in the intention-to-treat population. 
 
Results 
Between July 16, 2009, and March 7, 2011 (when enrolment was prematurely terminated), 284 
patients received initial bevacizumab and docetaxel; 185 (65%) were randomly assigned (91 to 
bevacizumab and capecitabine versus 94 to bevacizumab only). Progression-free survival was 
significantly longer in the bevacizumab and capecitabine group than in the bevacizumab only group 
(median 11·9 months [95% CI 9·8–15·4] vs 4·3 months [3·9–6·8]; stratified hazard ratio 0·38 [95% CI 
0·27–0·55]; two-sided log-rank p<0·0001), as was overall survival (median 39·0 months [95% CI 
32·3–not reached] vs 23·7 months [18·5–31·7]; stratified HR 0·43 [95% CI 0·26–0·69]; two-sided log-
rank p=0·0003). Results for time to progression were consistent with those for progression-free 
survival. 78 (86%) patients in the bevacizumab and capecitabine group and 72 (77%) in the 
bevacizumab only group had an objective response. Clinical benefit was recorded in 92 (98%) patients 
in the bevacizumab alone group and 90 (99%) in the bevacizumab and capecitabine group. Mean 
change from baseline in global health score did not differ significantly between groups. Grade 3 or 
worse adverse events during the maintenance phase were more common with bevacizumab and 
capecitabine than with bevacizumab only (45 [49%] of 91 patients vs 25 [27%] of 92 patients). The 
most common grade 3 or worse events were hand–foot syndrome (28 [31%] in the bevacizumab and 
capecitabine group vs none in the bevacizumab alone group), hypertension (eight [9%] vs three [3%]), 
and proteinuria (three [3%] vs four [4%]). Serious adverse events were reported by ten (11%) patients 
in the bevacizumab and capecitabine group and seven (8%) patients in the bevacizumab only group. 
 
Conclusion 
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Despite prematurely terminated accrual and the lack of information about post-progression treatment, 
both progression-free survival and overall survival were significantly improved with bevacizumab and 
capecitabine compared with bevacizumab alone as maintenance treatment. These results might 
inform future maintenance trials and current first-line treatment strategies for HER2-negative 
metastatic breast cancer. 
 
1.3 Adjuvant trastuzumab (Herceptin®) in node-positive, HER2 
positive breast cancer patients  
Drug description: a humanized antibody designed to target and block the function of HER2 
protein overexpressing cells 
Incidence in Austria: 5,400 breast cancer patients 
EMA/FDA licensingfor this indication: -/- 
Phase III results: 
• Perez et al. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for 
Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint 
Analysis of Data From NCCTG N9831 and NSABP B-31; JCO (2011) 29 (25); 3366-3373. 
 
Background 
Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor 
receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim 
analyses of four large trials. Initial data of the combined analysis of the North Central Cancer 
Treatment Group (NCCTG) N9831 Intergroup trial and National Surgical Adjuvant Breast and Bowel 
Project (NSABP) B-31 trial were reported in 2005. Long-term follow-up results on disease-free survival 
(DFS) and overall survival (OS) have been awaited. 
 
Methods 
Patients with HER2-positive operable breast cancer were randomly assigned to doxorubicin plus 
cyclophosphamide followed by paclitaxel with or without trastuzumab in the NCCTG N9831 and 
NSABP B-31 trials. The similar design of both trials allowed data from the control and trastuzumab 
containing arms to be combined in a joint analysis. 
 
Results 
At 3.9 years of median follow-up, there continues to be a highly statistically significant reduction in 
DFS event rate in favor of the trastuzumab-containing arm (P<.001). Similarly, there continues to be a 
statistically significant 39% reduction in death rate in favor of the trastuzumab-containing arm 
(P<.001). 
 
Conclusion 
These data demonstrate consistent DFS and OS advantages of adjuvant trastuzumab over time, with 
the longest follow-up reported to date. The clinical benefits continue to outweigh the risks of adverse 
effects. 
• Perez et al. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth 
Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival 
From NSABP B-31 and NCCTG N9831 JCO (2014) 32 (33); 3744-3752. 
 
Background 
Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with 
early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first 
reported in 2005. One of these reports, the joint analysis of North Central Cancer Treatment Group 
NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab in Treating Women With 
HER2-Overexpressing Breast Cancer) and the National Surgical Adjuvant Breast and Bowel Project 
NSABP B-31 (Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in 
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Treating Women With Node-Positive Breast Cancer That Overexpresses HER2), was updated in 
2011. We now report the planned definitive overall survival (OS) results from this joint analysis along 
with updates on the disease-free survival (DFS) end point. 
 
Methods 
In all, 4,046 patients with HER2-positive operable breast cancer were enrolled to receive doxorubicin 
and cyclophosphamide followed by paclitaxel with or without trastuzumab in both trials. The required 
number of events for the definitive statistical analysis for OS (710 events) was reached in September 
2012. Updated analyses of overall DFS and related subgroups were also performed.  
 
Results 
Median time on study was 8.4 years. Adding trastuzumab to chemotherapy led to a 37% relative 
improvement in OS (hazard ratio [HR], 0.63; 95% CI, 0.54 to 0.73; P<.001) and an increase in 10-year 
OS rate from 75.2% to 84%. These results were accompanied by an improvement in DFS of 40% (HR, 
0.60; 95% CI, 0.53 to 0.68; P<.001) and increase in 10-year DFS rate from 62.2% to 73.7%. All patient 
subgroups benefited from addition of this targeted anti-HER2 agent. 
 
Conclusion 
The addition of trastuzumab to paclitaxel after doxorubicin and cyclophosphamide in early-stage 
HER2-positive breast cancer results in a substantial and durable improvement in survival as a result of 
a sustained marked reduction in cancer recurrence. 
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2 Melanoma 
2.1 Cobimetinib (GDC-0973, XL-518) for the first-line therapy of 
unresectable locally advanced or metastatic melanoma 
Drug description: a MEK inhibitor 
Incidence in Austria: advanced melanoma with BRAF mutations: 25-33 
EMA/FDA licensing for this indication: -/- 
Phase III results:  
 
Larkin et al. Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma NEJM (2014) 371: 1867-
1876. 
 
Background  
The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients 
with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. 
This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the 
MEK inhibitor cobimetinib. 
 
Methods  
We randomly assigned 495 patients with previously untreated unresectable locally advanced or 
metastatic BRAF V600 mutation–positive melanoma to receive vemurafenib and cobimetinib 
(combination group) or vemurafenib and placebo (control group). The primary end point was 
investigator-assessed progression-free survival. 
 
Findings  
The median progression-free survival was 9.9 months in the combination group and 6.2 months in the 
control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 
to 0.68; P<0.001). The rate of complete or partial response in the combination group was 68%, as 
compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the 
combination group and 4% in the control group. Progression-free survival as assessed by independent 
review was similar to investigator-assessed progression-free survival. Interim analyses of overall 
survival showed 9-month survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% 
(95% CI, 65 to 80) in the control group. Vemurafenib and cobimetinib was associated with a 
nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with 
vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-
drug discontinuation. The number of secondary cutaneous cancers decreased with the combination 
therapy. 
 
Interpretation  
The addition of cobimetinib to vemurafenib was associated with a significant improvement in 
progression-free survival among patients with BRAF V600–mutated metastatic melanoma, at the cost 
of some increase in toxicity. 
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2.2 Nivolumab (BMS-936558, MDX1106, ONO4538) as first line 
therapy for unresectable or metastatic melanoma 
 
Drug description: a fully human IgG4 monoclonal antibody targeting the programmed cell 
death-1 receptor (PD-1) 
Incidence in Austria: advanced melanoma 640/year 
EMA/FDA licensing for this indication: -/- 
Phase III results:  
 
Robert et al.Nivolumab in Previously Untreated Melanoma without BRAF Mutation NEJM (2014) 
- online first; DOI: 10.1056/NEJMoa1412082 
 
Background  
Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 
study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in 
previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled 
study. 
 
Methods  
We randomly assigned 418 previously untreated patients who had metastatic melanoma without a 
BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks 
and dacarbazine-matched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square 
meter of body-surface area every 3 weeks and nivolumab- matched placebo every 2 weeks). The 
primary end point was overall survival. 
 
Findings  
At 1 year, the overall rate of survival was 72.9% (95% confidence interval [CI], 65.5 to 78.9) in the 
nivolumab group, as compared with 42.1% (95% CI, 33.0 to 50.9) in the dacarbazine group (hazard 
ratio for death, 0.42; 99.79% CI, 0.25 to 0.73; P<0.001). The median progression-free survival was 5.1 
months in the nivolumab group versus 2.2 months in the dacarbazine group (hazard ratio for death or 
progression of disease, 0.43; 95% CI, 0.34 to 0.56; P<0.001). The objective response rate was 40.0% 
(95% CI, 33.3 to 47.0) in the nivolumab group versus 13.9% (95% CI, 9.5 to 19.4) in the dacarbazine 
group (odds ratio, 4.06; P<0.001). The survival benefit with nivolumab versus dacarbazine was 
observed across prespecified subgroups, including subgroups defined by status regarding the 
programmed death ligand 1 (PD-L1). Common adverse events associated with nivolumab included 
fatigue, pruritus, and nausea. Drugrelated adverse events of grade 3 or 4 occurred in 11.7% of the 
patients treated with nivolumab and 17.6% of those treated with dacarbazine. 
 
Conclusions  
Nivolumab was associated with significant improvements in overall survival and progression-free 
survival, as compared with dacarbazine, among previously untreated patients who had metastatic 
melanoma without a BRAF mutation. 
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3 Cervix cancer 
Bevacizumab (Avastin®) for stage IVB, recurrent or persistent 
carcinoma of the cervix 
Drug description: anti-VEGF antibody 
Incidence in Austria: 390 patients 
EMA/FDA licensing for this indication: -/- 
Phase III results: Tewari et al. Improved Survival with Bevacizumab in Advanced Cervical 
Cancer N Engl J Med (2014) 370; 734-743; 
 
Background 
Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression 
in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent 
activity in previously treated, recurrent disease. Most patients in whom recurrent cervical cancer 
develops have previously received cisplatin with radiation therapy, which reduces the effectiveness of 
cisplatin at the time of recurrence. We evaluated the effectiveness of bevacizumab and nonplatinum 
combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer. 
 
Methods 
Using a 2-by-2 factorial design, we randomly assigned 452 patients to chemotherapy with or without 
bevacizumab at a dose of 15 mg per kilogram of body weight. Chemotherapy consisted of cisplatin at 
a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 175 mg per 
square meter or topotecan at a dose of 0.75 mg per square meter on days 1 to 3, plus paclitaxel at a 
dose of 175 mg per square meter on day 1. Cycles were repeated every 21 days until disease 
progression, the development of unacceptable toxic effects, or a complete response was documented. 
The primary end point was overall survival; a reduction of 30% in the hazard ratio for death was 
considered clinically important 
 
Results 
Groups were well balanced with respect to age, histologic findings, performance status, previous use 
or nonuse of a radiosensitizing platinum agent, and disease status. Topotecan–paclitaxel was not 
superior to cisplatin–paclitaxel (hazard ratio for death, 1.20). With the data for the two chemotherapy 
regimens combined, the addition of bevacizumab to chemotherapy was associated with increased 
overall survival (17.0 months vs. 13.3 months; hazard ratio for death, 0.71; 98% confidence interval, 
0.54 to 0.95; P=0.004 in a one-sided test) and higher response rates (48% vs. 36%, P=0.008). 
Bevacizumab, as compared with chemotherapy alone, was associated with an increased incidence of 
hypertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 
1%), and gastrointestinal fistulas of grade 3 or higher (3% vs. 0%). 
 
Conclusion 
The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or 
metastatic cervical cancer was associated with an improvement of 3.7 months in median overall 
survival. 
 
